Language reflects and shapes our thoughts, feelings, behaviours and experiences and can have a profound impact on the lives of people with and at risk for diabetes. Inappropriate language has a negative impact on self-efficacy, well-being and confidence of people living with diabetes, can seriously undermine experiences with health-care providers and, more broadly, can contribute to diabetes stigma. To date, Diabetes Canada has had no formal position to facilitate positive and affirming attitudes towards diabetes, which is reflected by the use of more appropriate language around diabetes. This consensus statement was developed by Diabetes Canada, by a working group comprised of health-care professionals and lived experience subject matter experts (LESME: patient partners) and validated by volunteers from Diabetes Canada's Professional Section and Diabetes Action Canada's Patient Circles. The principles outlined in this document will be valuable in three broad domains: 1) Diabetes Canada's internal and external communications, 2) increasing public awareness of diabetes and reduction of stigma around diabetes and 3) enhancing the health, wellness and self-efficacy of persons living with diabetes. A major strategy to effect change in this third domain will be to disseminate these concepts broadly among all current (and future) health-care professionals to help integrate positive and supportive attitudes in everyday clinical practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcjd.2020.05.008 | DOI Listing |
Front Biosci (Landmark Ed)
January 2025
Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.
Background: Thyroid Hormones (THs) critically impact human cancer. Although endowed with both tumor-promoting and inhibiting effects in different cancer types, excess of THs has been linked to enhanced tumor growth and progression. Breast cancer depends on the interaction between bulk tumor cells and the surrounding microenvironment in which mesenchymal stem cells (MSCs) exert powerful pro-tumorigenic activities.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
January 2025
Department of Biomedical Sciences, Grand Valley State University, Allendale, MI 49401, USA.
Background: Diabetes mellitus is associated with morphological and functional impairment of the heart primarily due to lipid toxicity caused by increased fatty acid metabolism. Extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) have been implicated in the metabolism of fatty acids in the liver and skeletal muscles. However, their role in the heart in diabetes remains unclear.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
January 2025
Biomedical Institute for Multimorbidity (BIM), Hull York Medical School (HYMS), University of Hull, HU6 7RX Hull, UK.
Cardiovascular complications claim the lives of up to 70% of patients with diabetes mellitus (DM). The mechanisms increasing cardiovascular risk in DM remain to be fully understood and successfully addressed. Nonetheless, there is increasing evidence in the scientific literature of the participation of platelets in the cardiovascular complications of DM.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
January 2025
School of Cardiovascular and Metabolic Medicine & Sciences, British Heart Foundation Centre of Research Excellence, King's College London, SE5 9NU London, UK.
Cardiovascular disease (CVD) is the most prevalent cause of mortality and morbidity in the Western world. A common underlying hallmark of CVD is the plaque-associated arterial thickening, termed atherosclerosis. Although the molecular mechanisms underlying the aetiology of atherosclerosis remain unknown, it is clear that both its development and progression are associated with significant changes in the pattern of DNA methylation within the vascular cell wall.
View Article and Find Full Text PDFJ Diabetes Sci Technol
January 2025
Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medicine, New York, NY, USA.
In an article in the , Backfish and coauthors examined the dose accuracy and reliability of the Tempo Pen and Tempo Smart Button connected insulin pen system. This study sponsored by Eli Lilly and Company found that this system met the International Organization for Standardization 11608-1:2014 requirements for dose accuracy at a range of doses, as well as the data transfer requirements after all injections. While these results are very encouraging, they were based on simulated human factors data while data from a human factors validation study where individuals successfully dialed and administered correct doses was not reported.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!